Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound Vitamin for Injection (3) is a parenteral multivitamin combination containing three essential water-soluble vitamins: thiamine (vitamin B1), riboflavin (vitamin B2, as riboflavin sodium phosphate), and ascorbic acid (vitamin C). Developed and manufactured by Shanxi Pude Pharmaceutical and other regional manufacturers in China, it is approved for the prevention and treatment of vitamin deficiencies resulting from inadequate dietary intake, malabsorption, wasting diseases, or increased physiological demand (such as during pregnancy or lactation). Thiamine acts as a coenzyme in carbohydrate metabolism, riboflavin is crucial for cellular respiration and energy production, and ascorbic acid serves as a potent antioxidant and cofactor for collagen synthesis. The drug is administered intravenously after dilution in compatible infusion fluids.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on compound vitamin for injection (3).